# Rebamipide Versus Diquafosol and Cyclosporine for Perioperative Dry Eye in Cataract Surgery

> **NCT07397936** · PHASE4 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 55 (actual)

## Conditions studied

- Dry Eye Disease (DED)
- Cataract

## Interventions

- **DRUG:** Rebamipide 2% ophthalmic solution
- **DRUG:** Diquafosol 3% ophthalmic solution
- **DRUG:** Cyclosporine 0.05% ophthalmic solution

## Key facts

- **NCT ID:** NCT07397936
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-08-01
- **Primary completion:** 2025-05-01
- **Final completion:** 2025-05-01
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2026-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07397936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07397936, "Rebamipide Versus Diquafosol and Cyclosporine for Perioperative Dry Eye in Cataract Surgery". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07397936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*